Valuation: Gilead Sciences, Inc.

Market Cap 182B 157B 148B 135B 253B 17,400B 254B 1,773B 683B 8,827B 682B 667B 28,063B P/E 2026 *
-44.3x
P/E 2027 * 18.2x
Enterprise Value 198B 172B 162B 147B 276B 19,005B 278B 1,936B 746B 9,641B 745B 728B 30,651B EV / Sales 2026 *
6.46x
EV / Sales 2027 * 5.83x
Free-Float
99.88%
Yield 2026 *
2.25%
Yield 2027 * 2.29%
1 day+1.24%
1 week-0.95%
Current month-1.13%
1 month+4.75%
3 months+16.25%
6 months-1.63%
Current year+17.79%
1 week 123.68
Extreme 123.68
125.88
1 month 118.74
Extreme 118.74
130
Current year 100.42
Extreme 100.42
132
1 year 93.42
Extreme 93.42
132
3 years 57.58
Extreme 57.58
132
5 years 52.23
Extreme 52.23
132
10 years 46.23
Extreme 46.23
132
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%-0.95% - - 182B
+1.86%-0.96%+50.69%+92.40% 1,015B
-0.49%-3.24%+49.57%+62.65% 642B
-0.88%+2.07%+19.89%+70.38% 463B
-1.08%+1.97%+37.25%+36.75% 353B
-0.20%+2.02%+16.79%+23.63% 265B
-1.23%+1.06%+5.15%+9.71% 254B
-0.64%-12.75%+38.03%+45.44% 206B
-0.83%-5.14%-21.99%-58.44% 191B
-0.83%-3.04%+27.81%+89.26% 182B
Average -0.23%-3.35%+24.80%+41.31% 396.69B
Weighted average by Cap. +0.16%-2.21%+33.62%+56.75%

Financials

2026 *2027 *
Net sales 30.7B 26.6B 25.11B 22.78B 42.73B 2,943B 43.04B 300B 116B 1,493B 115B 113B 4,746B 32.68B 28.32B 26.73B 24.25B 45.48B 3,132B 45.81B 319B 123B 1,589B 123B 120B 5,052B
Net income -4.27B -3.7B -3.5B -3.17B -5.95B -410B -5.99B -41.75B -16.09B -208B -16.06B -15.7B -661B 10.28B 8.9B 8.4B 7.62B 14.3B 985B 14.4B 100B 38.67B 500B 38.59B 37.74B 1,588B
Net Debt 16.75B 14.51B 13.69B 12.42B 23.3B 1,605B 23.47B 164B 63.02B 814B 62.89B 61.51B 2,588B 9.12B 7.91B 7.46B 6.77B 12.7B 875B 12.79B 89.11B 34.34B 444B 34.27B 33.52B 1,410B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
15/09/26 EUR 124.46 +0.35% 130
14/09/26 EUR 124.02 -0.58% 25
11/09/26 EUR 124.74 +0.86% 0
10/09/26 EUR 123.68 -1.31% 145
09/09/26 EUR 125.32 -0.27% 150
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
146.41USD
Average target price
158.15USD
Spread / Average Target
+8.02%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!